Journal of Skin and Stem Cell

Published by: Kowsar

Propranolol in Infantile Hemangioma: A Review Article

Parvin Mansouri 1 , Somayeh Hejazi 1 , Maryam Ranjbar 2 and Safoura Shakoei 1 , *
Authors Information
1 Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran
2 Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • Journal of Skin and Stem Cell: October 1, 2014, 1 (2); e22884
  • Published Online: October 7, 2014
  • Article Type: Review Article
  • Received: August 18, 2014
  • Accepted: August 18, 2014

To Cite: Mansouri P, Hejazi S, Ranjbar M, Shakoei S. Propranolol in Infantile Hemangioma: A Review Article, J Skin Stem Cell. 2014 ; 1(2):e22884.

Abstract
Copyright © 2014, Skin and Stem Cell Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Epidemiology
3. Pathogenesis
4. Clinical Presentation
5. Propranolol
7. Topical Propranolol
8. Propranolol in Rare and Complicated Forms of Infantile Hemangiomas
9. Indication of Treatment
10. Dose of Propranolol
11. Duration of Treatment
12. Monitoring the Patients
13. Side Effects of Propranolol
14. Resistance to Propranolol
Acknowledgements
Footnotes
References
  • 1. Zheng JW, Zhang L, Zhou Q, Mai HM, Wang YA, Fan XD, et al. A practical guide to treatment of infantile hemangiomas of the head and neck. Int J Clin Exp Med. 2013; 6(10): 851-60[PubMed]
  • 2. Greenberger S, Bischoff J. Pathogenesis of infantile haemangioma. Br J Dermatol. 2013; 169(1): 12-9[DOI][PubMed]
  • 3. Hernandez JA, Chia A, Quah BL, Seah LL. Periocular capillary hemangioma: management practices in recent years. Clin Ophthalmol. 2013; 7: 1227-32[DOI][PubMed]
  • 4. Melo JN, Rotter A, Rivitti-Machado MC, Oliveira ZN. Propranolol for treatment of infantile hemangiomas. An Bras Dermatol. 2013; 88(6 Suppl 1): 220-3[DOI][PubMed]
  • 5. Tu JB, Ma RZ, Dong Q, Jiang F, Hu XY, Li QY, et al. Induction of apoptosis in infantile hemangioma endothelial cells by propranolol. Exp Ther Med. 2013; 6(2): 574-8[DOI][PubMed]
  • 6. Sondhi V, Patnaik SK. Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol. J Pediatr Hematol Oncol. 2013; 35(7): 493-9[DOI][PubMed]
  • 7. Stiles J, Amaya C, Pham R, Rowntree RK, Lacaze M, Mulne A, et al. Propranolol treatment of infantile hemangioma endothelial cells: A molecular analysis. Exp Ther Med. 2012; 4(4): 594-604[DOI][PubMed]
  • 8. Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics. 2013; 131(1): 99-108[DOI][PubMed]
  • 9. Mantadakis E, Tsouvala E, Deftereos S, Danielides V, Chatzimichael A. Involution of a Large Parotid Hemangioma with Oral Propranolol: An Illustrative Report and Review of the Literature. Case Rep Pediatr. 2012; 2012: 5[DOI]
  • 10. Luu M, Frieden IJ. Haemangioma: clinical course, complications and management. Br J Dermatol. 2013; 169(1): 20-30[DOI][PubMed]
  • 11. Chandran S, Ari D, Jose J. Use of propanolol for treatment of large infantile haemangiomas-a report of two cases and review of the literature. Ann Acad Med Singapore. 2013; 42(5): 253-6[PubMed]
  • 12. Hemangioma Investigator G, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr. 2007; 150(3): 291-4[DOI][PubMed]
  • 13. Gao W, Qiao X, Ma S, Ma J, Dong X, Qin T, et al. Contribution of skin trauma to infantile skin hemangioma. Med Hypotheses. 2011; 76(4): 512-3[DOI][PubMed]
  • 14. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010; 163(2): 269-74[DOI][PubMed]
  • 15. Kleinman ME, Greives MR, Churgin SS, Blechman KM, Chang EI, Ceradini DJ, et al. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol. 2007; 27(12): 2664-70[DOI][PubMed]
  • 16. Xiao Q, Li Q, Zhang B, Yu W. Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence. Pediatr Surg Int. 2013; 29(6): 575-81[DOI][PubMed]
  • 17. Izadpanah A, Izadpanah A, Kanevsky J, Belzile E, Schwarz K. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg. 2013; 131(3): 601-13[DOI][PubMed]
  • 18. Callahan AB, Yoon MK. Infantile hemangiomas: A review. Saudi J Ophthalmol. 2012; 26(3): 283-91[DOI][PubMed]
  • 19. Kunzi-Rapp K. Topical propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2012; 29(2): 154-9[DOI][PubMed]
  • 20. Herschthal J, Wulkan A, George M, Waibel J. Additive effect of propranolol and pulsed dye laser for infantile hemangioma. Dermatol Online J. 2013; 19(6): 18570[PubMed]
  • 21. Wong A, Hardy KL, Kitajewski AM, Shawber CJ, Kitajewski JK, Wu JK. Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells. Plast Reconstr Surg. 2012; 130(5): 1012-21[DOI][PubMed]
  • 22. Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013; 131(1): 128-40[DOI][PubMed]
  • 23. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009; 26(5): 610-4[DOI][PubMed]
  • 24. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008; 358(24): 2649-51[DOI][PubMed]
  • 25. Ng SY, Kader Ibrahim SB. A Case of PHACES Syndrome with Successful Treatment of Facial Haemangioma With Propranolol. Med J Malaysia. 2013; 68(4): 364-5[PubMed]
  • 26. Al Dosari S, Riad H. Ulcerated nasal infantile haemangioma treated by oral propranolol. Dermatol Online J. 2013; 19(5): 18298[PubMed]
  • 27. Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, Heerema-McKenney AE. beta-Adrenergic receptor expression in vascular tumors. Mod Pathol. 2012; 25(11): 1446-51[DOI][PubMed]
  • 28. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35(4): 495-516[DOI][PubMed]
  • 29. Causse S, Aubert H, Saint-Jean M, Puzenat E, Bursztejn AC, Eschard C, et al. Propranolol-resistant infantile haemangiomas. Br J Dermatol. 2013; 169(1): 125-9[DOI][PubMed]
  • 30. Bonifazi E, Colonna V, Mazzotta F, Balducci G, Laforgia N. Propranolol in rapidly growing hemangiomas. Eur J Pediatr Dermatol. 2008; 18(3): 185-92
  • 31. de Graaf M, Breur JM, Raphael MF, Vos M, Breugem CC, Pasmans SG. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol. 2011; 65(2): 320-7[DOI][PubMed]
  • 32. Neri I, Balestri R, Patrizi A. Hemangiomas: new insight and medical treatment. Dermatol Ther. 2012; 25(4): 322-34[DOI][PubMed]
  • 33. Bagazgoitia L, Torrelo A, Gutierrez JC, Hernandez-Martin A, Luna P, Gutierrez M, et al. Propranolol for infantile hemangiomas. Pediatr Dermatol. 2011; 28(2): 108-14[DOI][PubMed]
  • 34. Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol. 2013; 30(2): 182-91[DOI][PubMed]
  • 35. Hong E, Fischer G. Propranolol for recalcitrant ulcerated hemangioma of infancy. Pediatr Dermatol. 2012; 29(1): 64-7[DOI][PubMed]
  • 36. Hermans DJ, Bauland CG, Zweegers J, van Beynum IM, van der Vleuten CJ. Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions. Br J Dermatol. 2013; 168(4): 837-43[DOI][PubMed]
  • 37. Price CJ, Lattouf C, Baum B, McLeod M, Schachner LA, Duarte AM, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol. 2011; 147(12): 1371-6[DOI][PubMed]
  • 38. Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009; 124(3)-31[DOI][PubMed]
  • 39. Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol. 2010; 146(7): 775-8[DOI][PubMed]
  • 40. Pavlakovic H, Kietz S, Lauerer P, Zutt M, Lakomek M. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics. 2010; 126(6)-93[DOI][PubMed]
  • 41. Ahogo CK, Ezzedine K, Prey S, Colona V, Diallo A, Boralevi F, et al. Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. Br J Dermatol. 2013; 169(6): 1252-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments